Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study in a cohort of 369 PD cases and another cohort of 326 ethnically matched controls to investigate the association of tumor necrosis factor-alpha (TNF-alpha) promoter single nucleotide polymorphisms (SNPs) with the risk of PD.
|
17192953 |
2007 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1 β), and tumor necrosis factor-α (TNF-α) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
|
28856541 |
2018 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We conducted a case-control study in a cohort of 369 PD cases and another cohort of 326 ethnically matched controls to investigate the association of tumor necrosis factor-alpha (TNF-alpha) promoter single nucleotide polymorphisms (SNPs) with the risk of PD.
|
17192953 |
2007 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results from our study revealed that the TNF -308AA genotype might increase the risk of early onset of PD.
|
18362084 |
2008 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that the cytokine gene polymorphisms we investigated are not related to the development of PD in the Italian population; further studies are warranted to clarify the role of the TNF-α-308GG/IL-1β-511T+ combined genotype.
|
20880267 |
2011 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1beta-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-alpha-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16).
|
17562931 |
2007 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1beta-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-alpha-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16).
|
17562931 |
2007 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
For the first time, the multilocus approach by the set-association method has been applied for the analysis of a cluster of five genes [tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8, IL-1alpha and IL-10] involved in the brain neuroinflammatory pathway in Parkinson's disease (PD), in a well-defined group of 197 PD patients and 173 control subjects from Spain.
|
18284424 |
2008 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.
|
21472005 |
2011 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.
|
21318773 |
2001 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α, which is highly toxic to dopaminergic neurons, is implicated as a major mediator of neuroinflammation in PD.
|
30515090 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
No positive correlation between 3-HK and TNF-α was seen in PD.
|
31654722 |
2020 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the TNFalpha pathway contributes to the pathogenesis of sporadic PD using a genetic approach.
|
12203044 |
2002 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since depression is a common co-morbid condition with PD, we undertook this study to determine whether Hc-TeTx might also show antidepressant-like properties and whether central brain-derived neurotrophic factor (BDNF) and/or tumor necrosis factor (TNF)-alpha are also affected by it.
|
31125623 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, linear discriminant analysis revealed that serum TNF and CSF α-synuclein discriminated between PD and HC with a minimum of 82% sensitivity and 83% specificity.
|
28821274 |
2017 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These promising findings provide compelling reasons to perform DN-TNF gene transfer studies in nonhuman primates with the long-term goal of using it in the clinic to prevent the delayed and progressive degeneration of DA neurons that gives rise to motor symptoms in PD.
|
20959812 |
2011 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that the specificity of extrapyramidal to NS raises the intriguing question of whether specific inflammatory pathways involving TNF-α play a role in the pathogenesis of PD and therefore may be a therapeutic target.
|
29054587 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In CSF and serum, inflammatory factors behaved differently, with increased CSF TNFα indicating rapid PD progression, and increased IL-1β in serum.
|
29478949 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accordingly, IL-1β and TNF-α might be considered therapeutically to ameliorate skeletal muscle abnormalities characterizing PD.
|
30400118 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the potent antioxidant fraction of UD attenuated the pro-inflammatory cytokines (TNF-α and IL-β) and restored the level of dopamine and its metabolites in MPTP-induced PD in rats.
|
27624385 |
2017 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
After the 12-week intervention, compared with the placebo, probiotic intake downregulated gene expression of interleukin-1 (IL-1) (P = 0.03), IL-8 (P < 0.001) and tumor necrosis factor alpha (TNF-α) (P=0.04) in PBMC of subjects with PD.
|
30041526 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To detect the expression of high-mobility group box protein 1 (HMGB1) and toll-like receptor 4 (TLR4) and their downstream signaling factors-myeloid differentiation factor 88 (MyD88), nuclear factor kappa B (NF-κB), and tumor necrosis factor alpha (TNF-α)-in the sera of patients with Parkinson's disease (PD) in order to evaluate the relationship of the HMGB1-TLR4 axis with PD development and progression.
|
29670828 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the pro-inflammatory tumor necrosis factor (TNF) is known to be toxic to catecholaminergic cells (see Parkinson disease), and this may prevent anti-inflammatory effects in inflamed tissue.
|
29941879 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neuroinflammatory mechanisms mediated by activated glial and cytokines (TNF-α, IL-1β) might contribute to neuronal degeneration leading to Alzheimer's (AD) and Parkinson's disease (PD).
|
27776205 |
2017 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, FMD decreased the number of glial cells as well as the release of TNF-α and IL-1β in PD mice, showing that FMD also inhibited neuro-inflammation.
|
30815845 |
2019 |